BiotechTube
Avia Pharma

Avia Pharma

Stockholm, Sweden· Est.
aviapharma.se
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Avia Pharma is a fast-growing, privately-held commercial-stage pharmaceutical company based in Stockholm, Sweden. It has rapidly scaled to over €40 million in sales (2022) through a hybrid strategy of in-house product development and strategic licensing/acquisitions in its five core therapy areas. With a seasoned management team and an aggressive growth strategy targeting European market leadership, the company is expanding its geographic footprint from the Nordics into the DACH region while actively pursuing M&A to bolster its portfolio.

Women's HealthUrologyDermatologyAllergyGeneral OTC

Technology Platform

Focus on innovative drug delivery technologies and formulation science for small molecule pharmaceuticals, applied across five therapeutic areas. Platform also extends to complementary medical devices, cosmetics, and food supplements.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

Significant opportunity exists in geographic expansion, particularly in the large DACH market, and through strategic acquisitions to consolidate market share in its five core therapeutic areas.
The growing consumer health and self-care trend across Europe supports demand in its OTC and specialty segments.
Deepening its proprietary drug delivery platform could create more differentiated, higher-margin products.

Risk Factors

The aggressive M&A-led growth strategy carries integration and execution risks.
The company faces intense competition in crowded OTC and specialty pharma markets, with potential margin pressure from retailers and payers.
Successful expansion into the culturally and commercially distinct DACH region is not guaranteed and presents operational challenges.

Competitive Landscape

Avia Pharma competes in fragmented markets against large multinational OTC companies (e.g., Bayer, GSK, Johnson & Johnson), generic pharmaceutical firms, and strong regional pharmacy brands. Its competitive edge lies in its focused therapeutic expertise, hybrid licensing/development model, and deep Nordic commercial roots, which it is now extending into Central Europe.

More companies in Sweden →